Proteomics and the blood–brain barrier: how recent findings help drug development

References

• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173–185.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200:629–638.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437–449.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery. 2004;54:131–142.
   PubMed Web of Science ®Google Scholar
• Muoio V, Persson PB, Sendeski MM. The neurovascular unit - concept review. Acta Physiol. 2014;210:790–798.
   PubMed Web of Science ®Google Scholar
• Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6:650–661.
   PubMed Web of Science ®Google Scholar
• ElAli A, Thériault P, Rivest S. The role of pericytes in neurovascular unit remodeling in brain disorders. Int J Mol Sci. 2014;15:6453–6474.
   PubMed Web of Science ®Google Scholar
• Simard M, Arcuino G, Takano T, et al. Signaling at the gliovascular interface. J Neurosci. 2003;23:9254–9262.
   PubMed Web of Science ®Google Scholar
• Torbett BE, Baird A, Eliceiri BP. Understanding the rules of the road: proteomic approaches to interrogate the blood brain barrier. Front Neurosci. 2015;9:70.
   PubMed Web of Science ®Google Scholar
• Chun HB, Scott M, Niessen S, et al. The proteome of mouse brain microvessel membranes and basal lamina. J Cereb Blood Flow Metab. 2011;31:2267–2281.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Badaut J, Tang J, et al. The vascular neural network–a new paradigm in stroke pathophysiology. Nat Rev Neurol. 2012;8:711–716.
   PubMed Web of Science ®Google Scholar
• Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37:48–57.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008;130:98–106.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Ther. 2015;97:347–361.
   PubMed Web of Science ®Google Scholar
• Zuchero YJY, Chen X, Bien-Ly N, et al. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron. 2015. doi:10.1016/j.neuron.2015.11.024.
   PubMedGoogle Scholar
• Mertsch K, Maas J. Blood-brain barrier penetration and drug development from an industrial point of view. Curr Med Chem Nerv Syst Agents. 2002;2:187–201.
   Google Scholar
• Hawkins BT, Egleton RD. Pathophysiology of the blood-brain barrier: animal models and methods. Curr Top Dev Biol. 2007;80:277–309.
   Web of Science ®Google Scholar
• Zavitz K. Crossing the blood-brain barrier: profiling cognitive safety in clinical development [Internet]. Cambridge Cogn. 2015 [cited 2015 Nov 14]. Available from: www.cambridgecognition.com/blog/entry/crossing-the-blood-brain-barrier-profilingcognitive-safety-in-clinical-dev
   Google Scholar
• He Q-Y, Chiu J-F. Proteomics in biomarker discovery and drug development. J Cell Biochem. 2003;89:868–886.
   PubMed Web of Science ®Google Scholar
• Pottiez G, Flahaut C, Cecchelli R, et al. Understanding the blood-brain barrier using gene and protein expression profiling technologies. Brain Res Rev. 2009;62:83–98.
   PubMedGoogle Scholar
• Karamanos Y, Gosselet F, Dehouck M-P, et al. Blood-brain barrier proteomics: towards the understanding of neurodegenerative diseases. Arch Med Res. 2014;45:730–737.
   PubMed Web of Science ®Google Scholar
• Deracinois B, Flahaut C, Duban-Deweer S, et al. Comparative and quantitative global proteomics approaches: an overview. Proteomes. 2013;1:180–218.
   PubMedGoogle Scholar
• Shusta EV. Blood-brain barrier genomics, proteomics, and new transporter discovery. NeuroRx. 2005;2:151–161.
   PubMedGoogle Scholar
• Vandenhaute E, Sevin E, Hallier-Vanuxeem D, et al. Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery. Drug Discov Today. 2012;17:285–290.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res. 2007;24:1745–1758.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Hirayama M, Ito S, et al. Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics. Expert Rev Proteomics. 2014;11:303–313.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Ikeda C, Uchida Y, et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol Pharm. 2013;10:289–296.
   PubMed Web of Science ®Google Scholar
• Cecchelli R, Aday S, Sevin E, et al. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS One. 2014;9:e99733.
   PubMed Web of Science ®Google Scholar
• Heikkinen AT, Lignet F, Cutler P, et al. The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. Proteomics Clin Appl. 2015;9:732–744.
   PubMed Web of Science ®Google Scholar
• Pottiez G, Sevin E, Cecchelli R, et al. Actin, gelsolin and filamin-A are dynamic actors in the cytoskeleton remodelling contributing to the blood brain barrier phenotype. Proteomics. 2009;9:1207–1219.
   PubMed Web of Science ®Google Scholar
• Pottiez G, Deracinois B, Duban-Deweer S, et al. A large-scale electrophoresis- and chromatography-based determination of gene expression profiles in bovine brain capillary endothelial cells after the re-induction of blood-brain barrier properties. Proteome Sci. 2010;8:57.
   PubMed Web of Science ®Google Scholar
• Pottiez G, Duban-Deweer S, Deracinois B, et al. A differential proteomic approach identifies structural and functional components that contribute to the differentiation of brain capillary endothelial cells. J Proteomics. 2011;75:628–641.
   PubMed Web of Science ®Google Scholar
• Deracinois B, Duban-Deweer S, Pottiez G, et al. TNAP and EHD1 are over-expressed in bovine brain capillary endothelial cells after the re-induction of blood-brain barrier properties. PLoS One. 2012;7:e48428.
   PubMed Web of Science ®Google Scholar
• Deracinois B, Pottiez G, Chafey P, et al. Glial-cell-mediated re-induction of the blood-brain barrier phenotype in brain capillary endothelial cells: a differential gel electrophoresis study. Proteomics. 2013;13:1185–1199.
   PubMed Web of Science ®Google Scholar
• Haqqani AS, Kelly J, Baumann E, et al. Protein markers of ischemic insult in brain endothelial cells identified using 2D gel electrophoresis and ICAT-based quantitative proteomics. J Proteome Res. 2007;6:226–239.
   PubMed Web of Science ®Google Scholar
• Lu Q, Murugesan N, Macdonald JA, et al. Analysis of mouse brain microvascular endothelium using immuno-laser capture microdissection coupled to a hybrid linear ion trap with Fourier transform-mass spectrometry proteomics platform. Electrophoresis. 2008;29:2689–2695.
   PubMed Web of Science ®Google Scholar
• Bergerat A, Decano J, Wu C-J, et al. Prestroke proteomic changes in cerebral microvessels in stroke-prone, transgenic[hCETP]-Hyperlipidemic, Dahl salt-sensitive hypertensive rats. Mol Med. 2011;17:588–598.
   PubMed Web of Science ®Google Scholar
• Minagar A, Alexander JS, Kelley RE, et al. Proteomic analysis of human cerebral endothelial cells activated by glutamate/MK-801: significance in ischemic stroke injury. J Mol Neurosci. 2009;38:182–192.
   PubMed Web of Science ®Google Scholar
• Ning M, Sarracino DA, Kho AT, et al. Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke. 2011;42:37–43.
   PubMed Web of Science ®Google Scholar
• Onodera H, Arito M, Sato T, et al. Novel effects of edaravone on human brain microvascular endothelial cells revealed by a proteomic approach. Brain Res. 2013;1534:87–94.
   PubMed Web of Science ®Google Scholar
• Haqqani AS, Delaney CE, Tremblay T-L, et al. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS. 2013;10:4.
   PubMedGoogle Scholar
• Kumar A, Baycin-Hizal D, Shiloach J, et al. Coupling enrichment methods with proteomics for understanding and treating disease. Proteomics Clin Appl. 2015;9:33–47.
   PubMed Web of Science ®Google Scholar
• Mitsos A, Melas IN, Siminelakis P, et al. Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. PLoS Comput Biol. 2009;5:e1000591.
   PubMed Web of Science ®Google Scholar
• Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 1999;17:121–127.
   PubMed Web of Science ®Google Scholar
• Khan A, Khan AU. Biomarker discovery and drug development: a proteomics approach. J Proteomics Bioinform. 2012;05:v–vi.
   Google Scholar
• Ebhardt HA, Root A, Sander C, et al. Applications of targeted proteomics in systems biology and translational medicine. Proteomics. 2015;15:3193–3208.
   PubMed Web of Science ®Google Scholar
• Schultz L, Zurich M-G, Culot M, et al. Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. Toxicol In Vitro. 2015;30:138–165.
   PubMed Web of Science ®Google Scholar
• Chen H-J, Shen Y-C, Shiao Y-J, et al. Multiplex brain proteomic analysis revealed the molecular therapeutic effects of Buyang Huanwu Decoction on cerebral ischemic stroke mice. PLoS One. 2015;10:e0140823.
   Google Scholar
• Lionetto L, Gentile G, Bellei E, et al. The omics in migraine. J Headache Pain. 2013;14:55.
   PubMed Web of Science ®Google Scholar
• McCaffrey G, Staatz WD, Sanchez-Covarrubias L, et al. P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem. 2012;122:962–975.
   PubMed Web of Science ®Google Scholar
• Tome ME, Schaefer CP, Jacobs LM, et al. Identification of P-glycoprotein co-fractionating proteins and specific binding partners in rat brain microvessels. J Neurochem. 2015;134:200–210.
   PubMed Web of Science ®Google Scholar
• Kamiie J, Ohtsuki S, Iwase R, et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008;25:1469–1483.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117:333–345.
   PubMed Web of Science ®Google Scholar
• Jacob A, Declèves X, Scherrmann J-M. Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier. Biol Aujourdhui. 2012;206:177–183.
   PubMedGoogle Scholar
• Kubo Y, Ohtsuki S, Uchida Y, et al. Quantitative determination of luminal and abluminal membrane distributions of transporters in porcine brain capillaries by plasma membrane fractionation and quantitative targeted proteomics. J Pharm Sci. 2015;104:3060–3068.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ito K, Ohtsuki S, et al. Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells. J Neurochem. 2015;134:97–112.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Tachikawa M, Akaogi R, et al. Contribution of pannexin 1 and connexin 43 hemichannels to extracellular calcium-dependent transport dynamics in human blood-brain barrier endothelial cells. J Pharmacol Exp Ther. 2015;353:192–200.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Future perspectives. In: Di L, Kerns HE, editors. Blood-brain barrier in drug discovery. Optimizingbrain exposure of CNS drugs and minimizing brain side effects for peripheral drugs. Hoboken (NJ): Wiley; 2015. p. 569–579.
   Google Scholar
• Xing C, Hayakawa K, Lok J, et al. Injury and repair in the neurovascular unit. Neurol Res. 2012;34:325–330.
   PubMed Web of Science ®Google Scholar
• Peluffo H, Unzueta U, Negro-Demontel ML, et al. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnol Adv. 2015;33:277–287.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405.
   PubMed Web of Science ®Google Scholar